Augmentation of NK cell-mediated cytotoxicity to tumor cells by inhibitory NK cell receptor blockers.
D000818:Animals; D000950:Antigens, Ly / Q000187:drug effects* / Q000378:metabolism; D001435:Bacteriophages / Q000235:genetics; D002460:Cell Line; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D006183:H-2 Antigens / Q000378:metabolism; D064532:Histocompatibility Antigen H-2D; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D037181:Lectins, C-Type; D051379:Mice; D008807:Mice, Inbred BALB C; D055650:NK Cell Lectin-Like Receptor Subfamily A; D009369:Neoplasms / Q000276:immunology*; D019151:Peptide Library; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors*; D055630:Receptors, NK Cell Lectin-Like
D000950:Antigens, Ly; D006183:H-2 Antigens; D064532:Histocompatibility Antigen H-2D; C527088:Klra1 protein, mouse; D037181:Lectins, C-Type; D055650:NK Cell Lectin-Like Receptor Subfamily A; D019151:Peptide Library; D010455:Peptides; D011971:Receptors, Immunologic; D055630:Receptors, NK Cell Lectin-Like